Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial
Open Access
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 137 (2) , 444-451.e8
Abstract
No abstract availableKeywords
Funding Information
- ALK
- ALK
This publication has 33 references indexed in Scilit:
- Efficacy and safety of the SQ‐standardized grass allergy immunotherapy tablet in mono‐ and polysensitized subjectsAllergy, 2012
- SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trialJournal of Allergy and Clinical Immunology, 2012
- Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescentsJournal of Allergy and Clinical Immunology, 2011
- Efficacy and Safety of a Glutaraldehyde-Modified House Dust Mite Extract in Allergic RhinitisAmerican Journal of Rhinology & Allergy, 2010
- Sub-Lingual ImmunotherapyWorld Allergy Organization Journal, 2009
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey IAllergy, 2007
- A note on the power of Fisher's least significant difference procedurePharmaceutical Statistics, 2006
- Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health surveyBMJ, 2002
- Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivityAllergy, 1997